Etrasimod, also known as APD334, is a potent, centrally available, functional antagonists of the S1P1 receptor for use as next generation therapeutics for treating multiple sclerosis (MS) and other autoimmune diseases. APD334 has a favorable PK/PD profile, producing robust lymphocyte lowering at relatively low plasma concentrations in several preclinical species. APD334 was efficacious in a mouse experimental autoimmune encephalomyelitis (EAE) model of MS and a rat collagen induced arthritis (CIA) model and was found to have appreciable central exposure.
Properties:
Boiling point: 621.4±50.0 °C(Predicted)
density: 1.326±0.06 g/cm3(Predicted)
pka: 4.61±0.10(Predicted)
LPL Receptor Related Products:
Ki16425; Ki16198; AM095; Fingolimod hydrochloride; Siponimod; Ozanimod; CYM5520; JTE-013; Ponesimod; AM966; CYM50308; NIBR-0213; VPC-23019; ONO-7300243